NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-MH-20-036 from the NIH Guide for Grants and Contracts
Notice NOT-HD-20-006 from the NIH Guide for Grants and Contracts
Notice NOT-HL-20-752 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-029 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-028 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-025 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-20-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is aimed at discovering, characterizing the selectivity and sensitivity, and externally validating biological measures to be used for assessing, prognosing, and monitoring recovery of adolescents who either clinically present with or are at risk for developing prolonged/persistent concussive symptoms following exposure to repetitive head impacts and/or concussion. Resultant biological measures should be incorporated into risk stratification algorithms to inform clinical care and patient stratification for future clinical trials. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data to further advance research in the area of persistent concussive symptoms in early and middle adolescent (EMA; ages 11-17 years old) populations.
Funding Opportunity RFA-OD-20-011 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence.
Funding Opportunity RFA-OD-20-010 from the NIH Guide for Grants and Contracts. The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers.
Funding Opportunity RFA-OD-20-009 from the NIH Guide for Grants and Contracts. The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent NIH research support during this transition in order to help awardees launch competitive, independent research careers.
Funding Opportunity RFA-OD-20-008 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence
Funding Opportunity PAR-20-110 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications specific to infrastructure that will support the storage, analysis, and sharing of primary and secondary data for the genetics and genomics of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).
Notice NOT-OD-20-070 from the NIH Guide for Grants and Contracts
Notice NOT-DA-20-013 from the NIH Guide for Grants and Contracts
Notice NOT-DA-20-031 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-20-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are combined in these studies must already have shown individual immune modulating activity. Understanding the molecular and cellular mechanisms underlying the synergistic enhancement of immune responses by combination adjuvants will facilitate the rational selection of components for vaccines tailored to specific pathogens. The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAIDs overall adjuvant research objectives. The long-term goal is to promote the development of novel adjuvant combinations which will improve the immunogenicity of vaccines while limiting or eliminating reactogenicity.
Funding Opportunity PAR-20-098 from the NIH Guide for Grants and Contracts. The purpose of this PAR is to support the development and evaluation of non-viral technologies to deliver genome editors to disease relevant somatic cells and tissues in vivo. The ultimate goal of these technologies is translation into clinical trials of genome editing to treat human disease.
Funding Opportunity PAR-20-109 from the NIH Guide for Grants and Contracts. The purpose of this PAR is to support the development and evaluation of non-viral technologies to deliver genome editors to disease relevant somatic cells and tissues in vivo. The ultimate goal of these technologies is translation into clinical trials of genome editing to treat human disease.
Notice NOT-AI-20-030 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-027 from the NIH Guide for Grants and Contracts